EMD 1.89% 5.2¢ emyria limited

Ann: December 2023 Quarterly Activities Report and Appendix 4C, page-13

  1. 212 Posts.
    lightbulb Created with Sketch. 12
    I don't like this quarterly report, giving me a feeling that P3 trial might go to the dead end, and management just want to colour paint the story by hiding the truth and shifting focus to MDMA. As I said several months ago, I should never invest in a WA bio tech company
 
watchlist Created with Sketch. Add EMD (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.